










BUCHWALD PHOSPHINE LIGANDS



 **S P E**


Summit Pharmaceuticals Europe

Buchwald Phosphine Ligands



Licensed by MIT

PH₃



**Buchwald
Ligands**


100 kg Production has been industrialized

NCI's advantages


- | | |
|-----------------------------------|--|
| ➤ Cost Effective: | Integrated Production from PH ₃ |
| ➤ High Purity: | More than 98.0% |
| ➤ Industrial Scale Supply: | Flexible and Capable |
| ➤ Contract Manufacturing Service: | Ask us to find your solution |

Application examples


Amination and amidation of arylsulfonates




Pd catalyzed Suzuki-Miyaura coupling reaction




Chemoselective amination of aryl-chlorides




Applications in Pharmaceutical Synthesis



J. Am. Chem. Soc., 2015, **137**, 13728.





Bioorg. Med. Chem. Lett. 2004, **14**, 2955.




Org. Lett. 2003, **5**, 1369.

P-Chiral Phosphine Ligand QuinoxP*




(R,R)-QuinoxP*




100 kg Production has been industrialized

- Air-stable crystalline solid
- Excellent enantioselectivities of up to 99.9% ee in asymmetric hydrogenation and C-C or C-N bond formations
- (S,S)-QuinoxP* is also available.
- QuinoxP* is patented by NCI.




Application examples

Enantioselective Hydrogenation



S/C 1,000 97.7% ee


VLA-4 antagonist S9059



S/C 10,000 99.9% ee


Casopitant

Enantioselective C-C or C-N bond forming reaction



Elbasvir

J. Am. Chem. Soc., 2015, 137, 13728.



J. Am. Chem. Soc., 2016, 138, 4338.

